Texas Oncology subsidiary Precision Health Informatics are partnering with Boston-based Concerto HealthAI to expand their precision medicine treatment of cancer patients. Concerto HealthAI works with Real World Data and artificial intelligence to zoom in the causes of cancer and provide solutions to patient disease.
“Precision Health Informatics’ model uses information from the molecular profile representing the genetics of the patient’s disease combined with the clinical information specific to that patient to develop personalized medicine solutions that are integral to diagnosing cancer and offering physicians and patients effective treatment options,” said Lori Brisbin, Vice President for Precision Health Informatics via release. “Concerto HealthAI’s leadership in solutions for precision medicine will help us derive more meaningful insights from patient data, that in turn may help us connect patients with appropriate clinical trials.”
The collaboration will use RWD, which comes from a number of sources in real-world settings such as patient surveys, clinical trials, and other studies, to characterize disease on the molecular level so that new therapies can be developed.
“Ultimately, this is all about developing and connecting cancer patients to precise, effective treatment,” said Dr. R. Steven Paulson, President of Precision Health Informatics, and President and Chairman of Texas Oncology via release. “Concerto HealthAI’s deep expertise in research-grade RWD solutions and AI technologies make it the ideal collaborator with Precision Health Informatics to help us more quickly develop medical innovations that benefit patients in our practice and elsewhere.”
“At Concerto HealthAI, we seek clinical collaborators committed to advancing insights and new treatment strategies for patients with the highest unmet medical needs,” said Jeff Elton, PhD, CEO of Concerto HealthAI via release. “Precision Health Informatics is making a deep commitment to enabling precision medicine, which we see as highly complementary to the work of our biomedical innovator partners.”
